Phase II Trial of RAD001 in Refractory Colorectal Cancer

Last updated: October 5, 2007
Sponsor: Swedish Medical Center
Overall Status: Completed

Phase

2

Condition

Rectal Cancer

Colon Cancer; Rectal Cancer

Colon Cancer

Treatment

N/A

Clinical Study ID

NCT00337545
CRAD0012467
Swedish Cancer Institute 05128
  • Ages > 18
  • All Genders

Study Summary

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens

  • Measurable disease

  • ECOG 0-2

Exclusion

Exclusion Criteria:

  • CNS disease

  • Chemotherapy or radiotherapy < 4 weeks prior

  • Active bleeding diathesis

Study Design

Total Participants: 22
Study Start date:
May 01, 2006
Estimated Completion Date:
April 30, 2007

Study Description

Study is completed and closed.

Connect with a study center

  • Swedish Cancer Institute

    Seattle, Washington 98104
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.